Modified tuberculosis vaccine as therapy against bladder cancer

March 5, 2020

The Max Planck Insitute for Infection Biology is sharing news of interest to the Immunology Community.

Therapy with VPM1002 is effective in bladder cancer patients

The human immune system can recognize and eliminate not only germs but also cancer cells. This is why treatments with weakened germs can help the immune system it ist fight against cancer.

The Max Planck Insitute for Infection Biology has developed a vaccine against TB which is currently in phase III trial. Less known is that this vaccine is also tested for treatment of bladder cancer and it has now shown a remarkable outcome in a clinical trial in preventing cancer recurrence.

clinical trial no.: NCT02371447 (https://clinicaltrials.gov/ct2/show/NCT02371447)

More News

Teaching Sustainable Development Goals: Methods for Education

January 15, 2025

Funding Opportunities: In Vitro Bioassay Systems Modeling Dysfunction in Neurodegenerative Diseases

January 15, 2025

IVVN ECR Career Development Fellowship Scheme

January 6, 2025

IUIS Executive Committee Statement on Membership Dues

December 20, 2024

ICW 2025 Meeting

December 11, 2024International Complement Society

SLB 2025- Inflammation: A Goldilocks Story

December 10, 2024Society for Leukocyte Biology

Spotlight on Veterinary Immunology: Highlights from ALACI 2024

December 10, 2024Veterinary Immunology Committee (VIC)

Announcing the Recipients of the 2024 Travel4Expertise Grant!

December 2, 2024Gender Equity Committee (GEC)

Clarification on Unaffiliated Events

October 29, 2024